HAYWARD, Calif. & REGINA, Saskatchewan--(BUSINESS WIRE)--RefleXion Medical, Inc., a therapeutic oncology company, and Limbus AI, Inc., a provider of software solutions for cancer radiation therapy, today announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.

加利福尼亚州海沃德（HAYWARD）和萨斯喀彻温省里贾纳（REGINA），一家治疗性肿瘤公司RefleXion Medical，Inc.，和癌症放射治疗软件解决方案提供商Limbus AI，Inc.，今天宣布了一项许可协议，将Limbus的自动轮廓软件Limbus Contour纳入RefleXion®X1放射治疗计划系统。

This integration will reduce the most significant bottleneck in the patient treatment planning process, which involves delineating the tumor target from surrounding critical organs and other healthy tissue.

这种整合将减少患者治疗计划过程中最重要的瓶颈，这涉及从周围关键器官和其他健康组织中描绘肿瘤靶标。

“Contouring is one of the most time-consuming tasks in radiotherapy planning, and often contributes to treatment delays,” said Sam Mazin, Ph.D., co-founder and chief technology officer at RefleXion. “We have found Limbus Contour’s AI-driven solution to be a technology leader in speed, accuracy and versatility.

RefleXion联合创始人兼首席技术官萨姆·马津（SamMazin）博士说：“轮廓是放射治疗计划中最耗时的任务之一，通常会导致治疗延迟。”。“我们发现Limbus Contour的人工智能驱动解决方案在速度、准确性和多功能性方面处于技术领先地位。

Depending on the complexity of the treatment plan, we expect contouring time reductions of up to 80%1, thus ensuring that patients receive timely treatment.

根据治疗计划的复杂性，我们预计轮廓时间减少高达80%1，从而确保患者得到及时治疗。

“Furthermore, this sets the stage for adapting the treatment plan immediately prior to delivery to leverage the unique and rich anatomic and biologic information produced by the X1 in image-guided and SCINTIX procedures,” continued Mazin.

“此外，这为在分娩前立即调整治疗计划奠定了基础，以利用X1在图像引导和闪烁程序中产生的独特而丰富的解剖学和生物学信息，”Mazin继续说道。

Radiotherapy treatment planning begins with the patient undergoing computed tomography (CT) imaging of the tumor target. Clinicians then manually outline or “contour” both the treatment area and the nearby organs (known as organs at risk or OARs) where irradiation should be minimized. This manual process is time-consuming and often suffers from variability between clinicians, which can lead to inconsistencies in the quality of the treatment plan and limit its effectiveness.

放射治疗计划从患者接受肿瘤靶标的计算机断层扫描（CT）成像开始。然后，临床医生手动勾勒或“勾勒”治疗区域和附近器官（称为危险器官或OAR），应尽量减少辐射。这种手动过程耗时且临床医生之间经常存在差异，这可能导致治疗计划质量的不一致并限制其有效性。

Limbus Contour employs clinically validated, deep-learning segmentation algorithms with a high level of accuracy to reduce human error and help ensure precise radiation delivery to target areas and avoidance of OARs.

角膜缘轮廓采用经过临床验证的深度学习分割算法，具有很高的准确性，以减少人为错误，并有助于确保精确的辐射传递到目标区域并避免OAR。

“The performance of Limbus Contour software relies on the quality of the CT image,” said Karl Otto, Ph.D., CEO at Limbus AI. “X1 images demonstrate high resolution, exceptional contrast, and minimal noise and motion artifacts. This should enhance precision in distinguishing adjacent structures and yield consistent, reliable contouring results, ensuring patients receive the highest quality care possible.”

Limbus AI首席执行官Karl Otto博士说：“角膜缘轮廓软件的性能取决于CT图像的质量。X1图像显示出高分辨率、异常对比度以及最小的噪声和运动伪影。这应该提高区分相邻结构的精度，并产生一致、可靠的轮廓结果，确保患者获得尽可能高质量的护理。”

The X1 with SCINTIX® technology is a dual-treatment modality radiotherapy platform that can treat patients with FDA-cleared indicated solid tumors of any stage. Both treatment modalities, biologic and anatomic, will benefit from the efficiencies of Limbus Contour integration.

X1 with闪烁X®技术是一种双重治疗模式放射治疗平台，可以治疗FDA清除的任何阶段的实体瘤患者。生物和解剖学两种治疗方式都将受益于角膜缘轮廓整合的效率。

About RefleXion Medical

关于Reflection Medical

RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors.

Reflection是一家位于加利福尼亚州海沃德的私营肿瘤治疗公司，将闪烁生物引导放射治疗商业化，这是一种新型疗法，使用单一放射性示踪剂注射将癌细胞转化为实时生物信标，以控制外照射放射治疗向单个或多个肿瘤的传递。

SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers. In addition to SCINTIX therapy, the RefleXion X1 is also FDA-cleared for conventional image-guided external-beam radiotherapy for solid tumors located anywhere in the body.

闪烁疗法适用于FDG引导治疗由原发性肺癌和骨癌或其他原发性癌症转移引起的肺和骨肿瘤。除了闪烁治疗外，Reflection X1还被FDA批准用于位于身体任何部位的实体瘤的常规图像引导外照射放疗。

About Limbus AI

关于角膜缘AI

Limbus AI is dedicated to improving cancer care through the development of state-of-the-art software. The company’s machine learning-based products improve efficiency and clinical workflows in cancer radiation treatment planning. Limbus AI specializes in the creation of artificial intelligence (AI)-driven automatic contouring algorithms performed entirely on customers' existing clinical workstations within the security of their own local network.

Limbus AI致力于通过开发最先进的软件来改善癌症护理。该公司基于机器学习的产品提高了癌症放射治疗计划的效率和临床工作流程。Limbus AI专门创建人工智能（AI）驱动的自动轮廓算法，该算法完全在客户自己的本地网络安全范围内的现有临床工作站上执行。

These unique software solutions enable clinicians to create more accurate treatment plans more quickly, allowing for the delivery of more precise treatments throughout the course of care. Limbus AI is headquartered in Regina, Saskatchewan, Canada.

这些独特的软件解决方案使临床医生能够更快地创建更准确的治疗计划，从而在整个护理过程中提供更精确的治疗。Limbus AI总部位于加拿大萨斯喀彻温省的里贾纳。